Central Illinois Hematology Oncology Conference

Peoria, IL US
April 5, 2025

Overview

The Central Illinois Hematology Oncology Conference is an accredited continuous education to improve the care of cancer patients by educating cancer care providers about precision-guided management in hematology and oncology. Regional and national experts in the field will share comprehensive insights into the actionable molecular variations seen in common cancers. The event's format is tailored to promote active learning, enhance knowledge retention, and encourage practitioners to apply fresh insights into their clinical routines. Through didactics, case-centric discussions, and lively Q&A sessions, attendees can gain clarity, address uncertainties, and interact with the field's pioneers. This conference aims to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in hematology and oncology.  It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Hematologists/ Oncologists
  • Oncology Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses
  • Researchers and others

Organizing Committee 

Course Director:

Binay Shah, MD, MHA Binaytara Foundation

Conference Chair

Krishna Rao, MD, PhD - Southern Illinois University School of Medicine

Organizing Committee

Noor Naffakh, PharmD, MS, BCOP - University of Illinois, Chicago

Rakesh Mandal, MD - OSF Healthcare

Kimberly Ku, MD - Illinois CancerCare

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review common molecular abnormalities in various cancers and the optimal timing to test for these abnormalities.
  • Interpret the findings from next-generation sequencing and other biomarkers that indicate the likelihood of response to specific therapies while also understanding the inherent challenges.
  • Apply optimal strategies centered on molecular-targeted treatments in the management of patients with cancer.
  • Summarize emerging research, the mechanism of action, and the significance of new molecular-targeted treatments in managing cancer patients.

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-012-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

    ACPE Pharmacy
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Course opens: 
09/17/2024
Course expires: 
07/05/2025
Event starts: 
04/05/2025 - 8:00am PDT
Event ends: 
04/05/2025 - 5:00pm PDT
Cost:
$150.00

Program

Saturday, April 5th, 2025

All times below are listed in Central Standard Time (CST).

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome 

08:05 AM – 08:20 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Justin Marquart


08:20 AM – 09:10 AM  Session 1 - Precision Oncology: Innovations and Foundations

Session Chair: Krishna Rao, MD, PhD

08:20 AM – 08:35 AM  Circulating Tumor DNA (ctDNA): Current applications and future directions - Frank Weinberg, MD, PhD

08:35 AM – 09:10 AM  Case-Based Discussion - Peng Wang, MD


09:10 AM – 10:25 AM  Session 2 - Hematology: Precision Strategies for Blood Disorders

Session Chair: James L. Wade III, MD, FACP, FASCO

09:10 AM – 09:30 AM  Precision Oncology in Multiple Myeloma - Matías E. Sánchez, MD

09:30 AM – 09:50 AM  Molecular-Directed Management of Myeloid Disorders - Guru Subramanian Guru Murthy, MD, MS

09:50 AM – 10:10 AM  Personalized Treatment in CLL - Parameswaran Venugopal, MD

10:10 AM – 10:25 AM  Panel Discussion - Rakesh Mandal, MD


10:25 AM – 10:45 AM  Break & Exhibits


10:45 AM – 11:45 AM  Session 3 - Breast Cancer: Tailored Treatments

Session Chairs: Nusayba Bagegni, MD & Emily Albright, MD, MS

10:45 AM – 11:10 AM  Genomics in Breast Cancer: From Biomarkers to Clinical Decisions - Nusayba Bagegni, MD

11:10 AM – 11:45 AM  Case-Based Discussion: Precision Oncology in Early-Stage and Metastatic Breast Cancer - Noor Naffakh, PharmD, MS, BCOP; Ashley Mohan, DO


11:45 AM – 12:45 PM  Lunch & Exhibits

12:00 PM - 12:45 PM  Product Theater Sponsored by Johnson & Johnson in the Illinois Room


12:45 PM – 01:45 PM  Session 4 - GI Oncology 

Session Chair: Waqas Azhar, MD 

12:45 PM – 01:10 PM  Management of GI Cancers in the Era of Precision Oncology - Ardaman Shergill, MD

01:10 PM – 01:45 PM  Case-Based Discussion: Emerging Targets and Treatment Approaches in GI Oncology - Manik Amin, MD


01:45 PM – 02:45 PM  Session 5 - Lung Cancer

Session Chair: Ryan Nguyen, DO

01:45 PM – 02:10 PM  Precision-Guided Therapeutics in Lung Cancer - Koosha Paydary, MD, MPH, MSc

02:10 PM – 02:45 PM  Case-Based Discussion: Biomarker-Driven Treatment in NSCLC -  Faith Abodunrin, MD; Nan Sethakorn, MD, PhD


02:45 PM – 03:30 PM  Break & Exhibits

02:45 PM - 03:30 PM  Product Theater Sponsored by Pfizer in the Illinois Room


03:30 PM – 04:30 PM  Session 6 - GU Oncology

Session Chair: Kimberly Ku, MD

03:30 PM – 03:55 PM  Recent Advances in Molecular Guided Treatment of GU Cancers - Ariel Nelson, MD, MS

03:55 PM – 04:30 PM  Case-Based Discussion: Personalizing GU Cancer Management - Kimberly Ku, MD; Randy Sweis, MD


04:30 PM  Adjourn

Venue

Peoria Marriott Pere Marquette
501 Main St
Peoria, IL 61602
United States

Faculty

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair(s)

Krishna Rao, MD, PhD

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Emily Albright, MD MS

has no relevant financial relationships to disclose at this time.

Waqas Azhar, MD

has a financial relationship (Stock) with Edward Lifesciences;.
has a financial relationship (Stock) with Pfizer;.
has a financial relationship (Employment) with SIU School of Medicine;.
has a financial relationship (Stock) with Bayer;.
has a financial relationship (Stock) with Bristol meyer-Squibb;.
has a financial relationship (Stock) with Johnson & Johnson;.

Nusayba Bagegni, MD

has a financial relationship (Professional Services) with NCCN;.
has a financial relationship (Grant Or Contract) with Sermonix Pharmaceuticals LLC;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Professional Services) with Onclive;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Sarah Cannon Development Innovations;.
has a financial relationship (Professional Services) with Aptitude Health;.
has a financial relationship (Professional Services) with MJH LifeSciences;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Stemline Therapeutics ;.
has a financial relationship (Professional Services) with Curio Science;.
has a financial relationship (Grant Or Contract) with Biovica International;.
has a financial relationship (Grant Or Contract) with Xcovery Holdings;.
has a financial relationship (Grant Or Contract) with Ambrx;.

Ryan Nguyen, D.O.

has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Bristol Myer Squibb;.
has a financial relationship (Grant Or Contract) with Exelixis ;.

Krishna Rao, MD, PhD

has no relevant financial relationships to disclose at this time.

James Wade III, Associate Professor of Clinica Medicine, FEinberg School of Medicine, Northwestern University, Ret.

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Guru Subramanian Guru Murthy, MD, MS

has a financial relationship (Other) with BeiGene;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Autolus;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Kite;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with Rigel;.

Ariel Nelson, MD, MS

has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Adaptimmune;.

Koosha Paydary, MD MPH MSc

has no relevant financial relationships to disclose at this time.

Matias Sanchez, MD

has no relevant financial relationships to disclose at this time.

Ardaman Shergill, MD MSPH

has a financial relationship (Professional Services) with Advisory Board: Iterion therapeutics, Revolution Medicine, Ipsen, Merus, Guardant, Pfizer, Regeneron/Sanofi and Catalyst Pharmaceuticals. Honorarium /Travel/Lodging: CCF, CCS, Cure CRC Summit, Great debates, Takeda, OncLive, OSCO, ASCO , ACPMP, ;.

Parameswaran Venugopal, MD

has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Professional Services) with Regeneron;.

Frank Weinberg, MD, PhD

has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Jazz Pharmaceuticals;.
has a financial relationship (Other) with TEMPUS Labs;.
has a financial relationship (Other) with Regeneron;.
Case Presenter(s)

Faith Abodunrin, MD

has no relevant financial relationships to disclose at this time.

Manik Amin

has no relevant financial relationships to disclose at this time.

Kimberly Ku, MD

has a financial relationship (Grant Or Contract) with PRECEDE (Pancreatic Cancer Early Detection) Consortium ;.

Rakesh Mandal, Staff/Consulting Pathologist, OSF St Francis Medical Center

has no relevant financial relationships to disclose at this time.

Ashley Mohan

has no relevant financial relationships to disclose at this time.

Noor Naffakh, PharmD

has no relevant financial relationships to disclose at this time.

Nan Sethakorn, MD, PhD

has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Other) with Amgen;.

Randy Sweis, MD

has a financial relationship (Independent contractor) with Aveo;.

Peng Wang, MD PhD

has no relevant financial relationships to disclose at this time.
Planning committee(s)

Kimberly Ku, MD

has a financial relationship (Grant Or Contract) with PRECEDE (Pancreatic Cancer Early Detection) Consortium ;.

Accreditation

Acknowledgement of Commercial Support

This activity is supported with an Independent Medical Education grant from Gilead Sciences.

Available Credit

  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-012-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

    ACPE Pharmacy
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.

Exhibitors

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Register/Take course

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.